Gastroenterology

Gastroenterology

Volume 155, Issue 2, August 2018, Pages 337-346.e10
Gastroenterology

Original Research
Full Report: Clinical—Alimentary Tract
Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases

https://doi.org/10.1053/j.gastro.2018.04.012Get rights and content

Background & Aims

The risk of infection associated with tumor necrosis factor antagonists (anti-TNF) and thiopurines (combination therapy) is uncertain. We assessed the risk of serious and opportunistic infections in patients with inflammatory bowel disease (IBD) treated with thiopurine monotherapy, anti-TNF monotherapy, or combination therapy in a large cohort of patients in France.

Methods

We performed a nationwide population-based study of patients (18 years or older) with a diagnosis of IBD in the French national health insurance database; we collected data from January 1, 2009 until December 31, 2014. The risks of serious and opportunistic infections associated with exposure to combination therapy, anti-TNF, and thiopurine monotherapies were compared using marginal structural Cox proportional hazard models adjusted for baseline and time-varying sociodemographic characteristics, medications, and comorbidities.

Results

Among the 190,694 patients with IBD included in our analysis, 8561 serious infections and 674 opportunistic infections occurred. Compared with anti-TNF monotherapy, combination therapy was associated with increased risks of serious infection (hazard ratio [HR], 1.23; 95% confidence interval [CI], 1.05–1.45) and opportunistic infection (HR, 1.96; 95% CI, 1.32–2.91). Compared with thiopurine monotherapy, anti-TNF monotherapy was associated with increased risks of serious infection (HR, 1.71; 95% CI, 1.56–1.88), mycobacterial infection (HR, 1.98; 95% CI, 1.15–3.40), and bacterial infection (HR, 2.38; 95% CI, 1.23–4.58, respectively). Conversely, anti-TNF monotherapy was associated with decreased risk of opportunistic viral infection compared with thiopurine monotherapy (HR, 0.57; 95% CI, 0.38–0.87).

Conclusions

In a nationwide cohort study of patients with IBD in France, we found heterogeneity in risks of serious and opportunistic infections in patients treated with immune-suppressive regimens. These should be carefully considered and weighed against potential benefits for IBD treatment in patient management.

Section snippets

Data Sources

This cohort study was based on the French National Health Insurance database (Système National d'Information Inter-Régimes de l'Assurance Maladie, SNIIRAM),15 which covers 95% of the French population with different insurance schemes based on employment situation. The general health insurance scheme covers employees in the industry, business, and service sectors; public service employees, and students, accounting for approximately 88% of the French population. Because of data availability and

Characteristics of the Cohort

Among the 246,704 individuals 18 years or older identified with IBD before 2014, 190,694 were included in the main analysis (Figure 1). During follow-up, 128,285 (67.3%) had never been exposed to thiopurines and anti-TNFs, and 572 (24.9%), 26,255 (13.8%), and 12,023 (6.3%) had ever been exposed to thiopurine monotherapy, anti-TNF monotherapy, and combination therapy, respectively, accounting for 109,177; 57,835; and 11,143 person-years (PY) of follow-up.

Overall, patients were predominantly

Discussion

Based on a large population-based, nationwide cohort study, our findings suggest that among patients with IBD, the risks of serious and opportunistic infections are higher with combination therapy than with thiopurine monotherapy or anti-TNF monotherapy. In addition, the risks of serious infections and of mycobacterial and opportunistic bacterial infections are increased with anti-TNF monotherapy compared with thiopurine monotherapy. However, the risk of opportunistic infections with anti-TNF

References (32)

  • M. Harbord et al.

    Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management

    J Crohns Colitis

    (2017)
  • L. Beaugerie et al.

    Cancers complicating inflammatory bowel disease

    N Engl J Med

    (2015)
  • N. Nyboe Andersen et al.

    Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study

    BMJ

    (2015)
  • G.R. Lichtenstein et al.

    Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREATTM registry

    Am J Gastroenterol

    (2012)
  • C.G. Grijalva et al.

    Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases

    JAMA

    (2011)
  • Z. Lin et al.

    Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn’s disease

    Eur J Gastroenterol Hepatol

    (2011)
  • Cited by (0)

    Conflicts of interest Franck Carbonnel has received consulting fees from Genentech, Otsuka, and Vifor and lecture fees from Hospira. Fabrice Carrat has received consulting fees from Imaxio. The remaining authors disclose no conflicts.

    Funding There was no funding source for this study.

    Author names in bold designate shared co-first authorship.

    View full text